Zoetis, Inc. today announced that it received FDA approval for Simparica (sarolaner) chewables, a once-monthly flea and tick medication for dogs.

The 2023 head-to-head study compared three popular prescription flea and tick treatment products for dogs, Credelio (lotilaner), Simparica TRIO (sarolaner, moxidectin, pyrantel), and NexGard ...

Dose Confirmation of Sarolaner Administered Orally Against Induced Infestations of Dermacentor variabilis on Dogs (A166C-US-12-132, 2013; A166C-US-12-133, 2013). 9. Zoetis.

The study included dogs that were randomly allocated to one of four treatment groups: Credelio, Simparica TRIO, NexGard or untreated control. Elanco Animal Health Incorporated (NYSE: ELAN) is a ...

GREENFIELD, Ind., Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study ...